EA201991151A1 - NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION - Google Patents

NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION

Info

Publication number
EA201991151A1
EA201991151A1 EA201991151A EA201991151A EA201991151A1 EA 201991151 A1 EA201991151 A1 EA 201991151A1 EA 201991151 A EA201991151 A EA 201991151A EA 201991151 A EA201991151 A EA 201991151A EA 201991151 A1 EA201991151 A1 EA 201991151A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen
immunotherapy
new
application
tumor
Prior art date
Application number
EA201991151A
Other languages
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/081800 external-priority patent/WO2018104438A1/en
Publication of EA201991151A1 publication Critical patent/EA201991151A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к антигенраспознающим структурам к опухолеассоциированным антигенам (MAGEA1). В частности, в изобретении предложены новые молекулы на основе Т-клеточного рецептора (ТКР), являющиеся селективными и специфическими для экспрессируемого опухолями антигена по изобретению. ТКР по изобретению и связывающиеся с ТАА фрагменты, полученные из этого ТКР, применимы для диагностики, лечения и профилактики раковых заболеваний, при которых экспрессируется антиген ТАА. Предложены также нуклеиновые кислоты, кодирующие антигенраспознающие структуры по изобретению, векторы, содержащие данные нуклеиновые кислоты, рекомбинантные клетки, экспрессирующие эти антигенраспознающие структуры, и фармацевтические композиции, включающие соединения по изобретению.The present invention relates to antigen-recognizing structures for tumor-associated antigens (MAGEA1). In particular, the invention provides new molecules based on the T-cell receptor (TCR), which are selective and specific for the tumor-expressed antigen of the invention. The TKR according to the invention and the fragments binding to TAA obtained from this TKR are applicable for the diagnosis, treatment and prevention of cancer in which the TAA antigen is expressed. Nucleic acids encoding antigen-recognizing structures of the invention, vectors containing these nucleic acids, recombinant cells expressing these antigen-recognizing structures, and pharmaceutical compositions comprising the compounds of the invention are also provided.

EA201991151A 2016-12-08 2017-12-07 NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION EA201991151A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662431588P 2016-12-08 2016-12-08
PCT/EP2017/081800 WO2018104438A1 (en) 2016-12-08 2017-12-07 Novel t cell receptors and immune therapy using the same

Publications (1)

Publication Number Publication Date
EA201991151A1 true EA201991151A1 (en) 2019-11-29

Family

ID=66326301

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991151A EA201991151A1 (en) 2016-12-08 2017-12-07 NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION

Country Status (2)

Country Link
AR (1) AR110682A1 (en)
EA (1) EA201991151A1 (en)

Also Published As

Publication number Publication date
AR110682A1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
CY1124997T1 (en) NOVEL T-CELL RECEPTORS AND IMMUNOTHERAPY USING THEM
MX2019006724A (en) Novel t cell receptors and immune therapy using the same.
CL2020001181A1 (en) New genetically modified T-cell receptors and immune therapies using them.
MX2023003463A (en) T cell receptors and immune therapy using the same against prame positive cancers.
CO2020000357A2 (en) Novel T-cell receptors, and immunotherapy using the same
WO2018172533A3 (en) T cell receptors and immune therapy using the same against prame positive cancers
BR112019001922A2 (en) t-cell receptors and immunotherapy using the same
EA201891966A1 (en) MOLECULES ASSOCIATING BCMA AND METHODS OF THEIR APPLICATION
EA201791666A1 (en) CD3 ANTIBODIES, CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES THAT SPECIFICALLY CONNECT WITH CD3 AND / OR CD123
EA201791057A1 (en) ANTIGENSBELTING MOLECULES CONTAINING THERMAL LIGAND OF TNF FAMILIES
MX2020010094A (en) Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof.
MX2022007902A (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy.
EA201991151A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
EA202090712A1 (en) NEW GENETIC ENGINEERED T-CELL RECEPTORS AND IMMUNE THERAPY WITH THEIR USE
EA201990488A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
EA201992583A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
EA201991139A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
CY1124826T1 (en) T-CELL RECEPTORS AND IMMUNOTHERAPY USING THEM
EA201992002A1 (en) T-CELL RECEPTORS AND IMMUNE THERAPY OF PRAME-POSITIVE CANCER DISEASES WITH THEIR APPLICATION
AR113834A1 (en) GENETICALLY MODIFIED T-CELL RECEPTORS AND IMMUNE THERAPIES THAT USE THEM
AR109345A1 (en) T-LYMPHOCYTE AND IMMUNOTHERAPY RECEPTORS BASED ON THE USE OF THE SAME